Skip to content

Author

A. Saborowski

We have 5 of 175 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Evaluation of early C‐reactive protein kinetics as an early response marker in biliary tract cancer treated with combined chemoimmunotherapy: A multicenter observational study

Reliable prognostic biomarkers for treatment response in patients with biliary tract cancer (BTC) who receive chemoimmunotherapy are still lacking. The objective of this study was to evaluate the potential of early C‐reactive protein (CRP) kinetics as a tool for predicting survival in these patients.

G. Allo, Joshua Leutiger, C. Leyh et al. · 0 citations
Open access Oct 2026

Genomic and immune profiling characterizes immune heterogeneity and a TIGIT-associated subtype in intrahepatic cholangiocarcinoma

Background Intrahepatic cholangiocarcinoma (iCCA) is characterized by marked molecular and microenvironmental heterogeneity and moderate response to immunotherapy. We aimed to define the genomic and spatial determinants of immune checkpoint activity in iCCA and their association with clinical outcome. Methods We perfor...

A. Korosteleva, J. Reschke, Da-Wei Yi et al. · 0 citations
Open access Sep 2026

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real‐world study

A novel prognostic index for patients with locally advanced or metastatic biliary tract cancer treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab is explored and validated.

M. Persano, A. Casadei-Gardini, L. Fornaro et al. · 0 citations
Review Sep 2026

Precision oncology in GI-cancers: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance.

The evolving therapeutic landscape, emphasizing clinical efficacy, and indications for various treatment modalities are reviewed, with a focus on on-target mutations and convergent off-target MAPK signaling pathways.

L. Aceituno, E. Valenzi, O. Segatto et al. · 0 citations
Open access Aug 2026

Machine learning for population-level risk prediction of future cholangiocarcinoma

It is shown that ML models integrating biliary-disease associated health records and Gamma glutamyltransferase can stratify risk of future CCA, and demonstrates the potential of data-driven models in personalised screening for hepatobiliary cancer.

F. van Haag, J. Clusmann, Paul-Henry Koop et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.